Efficacy News and Research

RSS
Study provides support for new understanding of the immune system

Study provides support for new understanding of the immune system

Study demonstrates longer-term benefits of Lung Flute for COPD patients

Study demonstrates longer-term benefits of Lung Flute for COPD patients

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

Fecal occult blood screening increases diagnosis rate of high-risk polyps by 89%

Fecal occult blood screening increases diagnosis rate of high-risk polyps by 89%

Access to potentially life-extending cancer drugs varies worldwide

Access to potentially life-extending cancer drugs varies worldwide

Thirteen research projects to explore nondrug approaches to manage pain, other health conditions

Thirteen research projects to explore nondrug approaches to manage pain, other health conditions

CorMedix submits IND application to FDA for Neutrolin

CorMedix submits IND application to FDA for Neutrolin

NCCN ORP awards four research grants to advance development of nintedanib

NCCN ORP awards four research grants to advance development of nintedanib

Pitt researchers awarded new $5.8 million NIH grant to develop microfluidic 3D liver model system

Pitt researchers awarded new $5.8 million NIH grant to develop microfluidic 3D liver model system

ECT benefits demonstrated in randomised controlled trial

ECT benefits demonstrated in randomised controlled trial

Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

Antacids linked to reduced erlotinib efficacy

Antacids linked to reduced erlotinib efficacy

Alectinib promise for crizotinib-resistant NSCLC

Alectinib promise for crizotinib-resistant NSCLC

C Diff Foundation to present 2014 "Raising C.difficile Awareness" conference in November

C Diff Foundation to present 2014 "Raising C.difficile Awareness" conference in November

New Jersey physician offers FDA-approved non-invasive fat reduction treatment

New Jersey physician offers FDA-approved non-invasive fat reduction treatment

Promising new approach for combating colorectal cancer

Promising new approach for combating colorectal cancer

Distinct patterns of gene expression identified in several groups of pancreatic CTCs

Distinct patterns of gene expression identified in several groups of pancreatic CTCs

TauRx achieves target enrolment in second LMTX Phase III clinical trial for Alzheimer's disease

TauRx achieves target enrolment in second LMTX Phase III clinical trial for Alzheimer's disease

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.